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Resident memoryT cells (TRM) are broadly defined as a population ofT cells, which persist
in non-lymphoid sites long-term, do not re-enter the circulation, and are distinct from central
memory T cells (TCM) and circulating effector memory T cells (TEM). Recent studies have
described populations of TRM cells in the skin, gut, lungs, and nervous tissue. However, it
is becoming increasingly clear that the specific environment in which the TRM reside can
further refine their phenotypical and functional properties. Here, we focus on theTRM cells
that develop following respiratory infection and reside in the lungs and the lung airways.
Specifically, we will review recent studies that have described some of the requirements
for establishment of TRM cells in these tissues, and the defining characteristics of TRM in
the lungs and lung airways. With continual bombardment of the respiratory tract by both
pathogenic and environmental antigens, dynamic fluctuations in the local milieu including
homeostatic resources and niche restrictions can impactTRM longevity. Beyond a compre-
hensive characterization of lungTRM cells, special attention will be placed on studies, which
have defined how the microenvironment of the lung influences memory T cell survival at
this site. As memory T cell populations in the lung airways are requisite for protection yet
wane numerically over time, developing a comprehensive picture of factors which may
influence TRM development and persistence at these sites is important for improving T
cell-based vaccine design.
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INTRODUCTION
The adaptive immune system is defined by its ability to mount an
antigen-specific immune response and generate long-lived mem-
ory cells. CD8+ memory T cells (Tmem) respond rapidly upon
secondary encounter with the same antigen and can provide pro-
tection against the development of severe disease or chronic infec-
tion in the absence of neutralizing antibodies (1). This attribute
of Tmem is particularly attractive in the context of vaccine design
for viral infections such as HIV or influenza, which rapidly modify
antibody targets as a result of high mutagenic rates and immune
pressure.
The efficiency of Tmem-mediated protection is in part a direct
result of activated T cells initiating divergent developmental and
migratory programs, which provide the host with a multifac-
eted immune response following challenge. This Tmem diversity
is acquired as a result of different levels of co-stimulation, inflam-
mation, or T cell help, which not only vary throughout the course
of a single infection but are also impacted by infection route.
Initially, memory T cells were broadly categorized into two popula-
tions based on homing preferences, circulating between secondary
lymphoid organs as central memory T cells (TCM) or less dis-
cretely throughout the periphery, including non-lymphoid tissues,
defined as effector memory T cells (TEM) (2). These memory pools
are distinguished from one another by their differential expres-
sion of the lymph node homing molecules L-selectin (CD62L)
and CCR7, with TCM expressing high levels of these molecules for
lymph node entry and retention (3) and TEM cells expressing low
levels. While this simplified TCM/TEM paradigm predominated
Tmem classification for several years, subsequent studies using
parabiotic mice (4) and adoptive transfer systems (5) demon-
strated that at least one additional Tmem pool exists with tissue-
specific residency and little migratory potential. Additional studies
confirmed the existence of these tissue-locked Tmem at portals of
pathogen entry and led to the T resident memory cells (TRM)
nomenclature.
As relative newcomers to the T cell memory scene, TRM cells
have not been characterized to the same extent as TCM and TEM
cells, and our definition of this memory population, as well our
understanding of its origin is still evolving. Nonetheless, specific
CD8+ TRM populations have been identified in many peripheral
sites including the gut (6), skin (7), brain (8), female reproduc-
tive mucosa (9, 10), and the lung (11). Despite some similarities
with TEM, lack of equilibration of Tmem between specific tissues
of parabiotic mice as well as general “hallmarks” of TRM have
been identified as defining characteristics. These distinguishing
features include the expression of CD103 (αE integrin) and CD69,
molecules traditionally associated with adhesion within epithelial
layers and recent activation, respectively (12, 13). A recent paper by
Mackay et al. defined a common transcriptional signature shared
by CD103+ TRM cells isolated from the skin, gut, and lung con-
sisting of 37 genes differentially expressed compared to TEM or
TCM cells, demonstrating that TRM cells are a distinct Tmem lin-
eage (14). Additionally, this study determined that TRM cells from
distinct anatomical sites also possessed unique gene transcription
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patterns, with 127 being unique to the gut, 86 unique to the skin,
and 25 unique to the lung, indicating additional diversification
within the TRM pool, likely environmentally driven.
Despite the relative juvenescence of the TRM field, the impor-
tance of this cell population has been alluded to for some time.
TRM cells are positioned at the site of pathogen encounter as a
front line of defense, and several studies have highlighted their
role in defense against pathogenic challenges (7, 15–17). Indeed,
in the case of influenza virus infection, the number of antigen-
specific CD8+ T cells located within the respiratory tract correlates
with the highest degree of heterosubtypic immunity (18, 19), and
recently it has been shown that TRM specifically are responsible for
this protection (20). Defining the characteristics that lead to TRM
development, and determining how they persist at sites of infec-
tion may lead to novel ways to enhance vaccine efficacy. This review
will focus on the development, characteristics, and maintenance of
CD8+ TRM cells in the respiratory tract, which develop after acute
respiratory infection, primarily with influenza and Sendai viruses.
How the lung environment affects the developmental transition
and tissue residency of CD8+ TRM cells will be discussed, from the
primary activation of the antigen-specific cell through the return
to homeostasis and during resting conditions.
PART I: FACTORS INFLUENCING TRM DEVELOPMENT
There is great interest in deciphering the TRM developmental path-
way, as understanding this mechanism could lead to modulation
of the responses in ways, which could enhance the establishment
of this Tmem pool. The development of TRM cells will have two
main requirements: (1) the ability to survive through contrac-
tion (become a Tmem) and (2) the ability to differentiate into the
appropriate memory lineage (become a TRM cell as opposed to a
TEM or TCM cell). In this section, we will discuss factors that may
influence TRM development in the early priming environment of
the lymph node, and subsequently in the inflamed lung. Recent
evidence demonstrates that T cell differentiation into distinct TEM
and TCM subsets occurs soon after T cell priming (21), which begs
the question: does a population of cells that is destined to become
TRM cells also develop during or soon after initial activation in the
lymph node? Or, do TRM arise only after tissue-specific entry based
on specific cues within the microenvironment of tissues, like the
lung? These scenarios are not necessarily mutually exclusive and
full commitment to the TRM lineage is likely due to a combina-
tion of these two possibilities as will be further discussed and as
described in Figure 1.
EARLY DIFFERENTIATION SIGNALS IN THE LYMPH NODE: DEVELOPING
TRM POTENTIAL
Activation of CD8+ T cell requires three signals: detection of
cognate peptide/MHCI complex, co-stimulation, and a cytokine
signal (22). The combination of these three signals, which may
vary in intensity and type, results not only in clonal expansion
and acquisition of effector function, but also influences long-term
cellular fate (21). In many cases, the overall Tmem potential of
the antigen-specific CD8+ T cell is driven by lineage-associated
transcription factors and acquired epigenetic changes (23), which
can be experimentally monitored. These programing signals are
influenced by the type of (priming) APC, antigen availability,
and inflammatory properties of the pathogen, which can vary
based on the individual pathogen and the route, which infection
is acquired. While an early TRM lineage-specific transcriptional
program has not been identified, specific migratory signals facili-
tating peripheral tissue entry, with subsequent acquisition of TRM
characteristics implies that at least some early signals help polarize
cells toward a TRM fate. Here, we will discuss the possible early
signals encountered in the lung draining mediastinal lymph nodes
(MdLN), which may promote the development of respiratory TRM
cells.
During influenza infection, activated, antigen-laden respira-
tory DCs migrate to the MdLN to interact with naïve CD8+ T
cells. The majority of these migratory DCs fall into two subsets,
FIGURE 1 | Proposed developmental pathways forTRM cells following
respiratory infection. Priming by a CD103+ DC and appropriate cytokine
signals (left) results in the generation of either a common TEM/RM precursor cell
(green) or individual pre-TEM or TRM cells (blue and purple, respectively). Once
in the lung (right), environmental factors will drive subsequent cell fate
decisions, resulting in either terminal differentiation (and death) or the
generation of memory cells. While most current evidence supports the
differentiation route depicted in (A), where a common precursor differentiates
first into memory, followed by environmentally driven lineage differentiation
into TRM or TEM cells, it is plausible that differentiation into a TRM fate occurs
immediately following priming in the lymph node (B) and is distinguished by
yet to be discovered phenotypic or genetic markers.
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airway localized CD103+ DCs and lung parenchyma CDllbhi DCs
(24). In addition to their localization in the lung during a resting
state, these DC populations differ in their induction of CD8+ T
cell effector functions, with CD103+ DCs requisite for complete
effector differentiation, defined by expression of standard effector
markers and their potential to enter inflamed tissues (CD25hi, T-
bethi, and Blimp-1hi and CD62Llo CCR5hi). In contrast, CD11bhi
DCs are more likely to prime CD8+ T cells, which largely remained
in the lymph nodes, expressing molecules associated with the
development of TCM (CD62Lhi, T-betlo, Blimp-1lo CD25lo, and
CD127hi (25). Thus, as entry into peripheral tissues is a defining
characteristic of TRM cells, it is likely that TRM precursors are acti-
vated in the draining MdLN by activated respiratory CD103+DCs,
where they not only acquire effector function, but more impor-
tantly, the ability to accumulate in lung tissue, which is requisite for
TRM development. Priming by CD103+DCs may also be one of the
reasons that TRM have a propensity to develop following induction
of the responses in mucosal tissues, as similar CD103+ epidermal
associated DCs are found predominately in these sites (26) and
may be a common method promoting CD8+ T cell migration into
peripheral tissues. In support of this, intranasal vaccination gives
rise to populations of long lasting Tmem in the female reproduc-
tive tract, a phenomenon that is not observed following systemic
infection (27–29). This indicates that a common priming require-
ment (possibly CD103+ DCs) can induce CD8+ T cell migration
into more restrictive sites, and vaccination at certain mucosal sur-
faces may broadly confer protection at expanded peripheral sites
(30). However, it should be noted that certain systemic infections,
such as lymphocytic choriomeningitis virus (LCMV), can produce
populations of TRM cells in a wide variety of tissues, including the
intestinal tract, brain, and female reproductive tract, as well as
organs such as the kidney, heart, and pancreas, although in this
study respiratory TRM were not assessed (31). LCMV, a true sys-
temic pathogen, can replicate in multiple cell types and locations,
suggesting that pathogen promiscuity could result in activation of
CD103+ DC and induction of TRM independent of mucosal infec-
tion. For the lung, it seems that priming via the respiratory route
[intranasally (i.n.)] is necessary for TRM formation, as priming
with influenza virus intraperitoneally (i.p.) fails to generate TRM
cells (20). The difference here is that influenza will not produce
a productive infection when given by the i.p. route, limiting pre-
sentation to CD103− DCs (32). It will be important for future
studies to distinguish whether the lung is truly a restrictive site,
limiting TRM generation only after infection via the i.n. route, or
if a systemic or mucosal challenge at a divergent site can induce
lung TRM populations under the right conditions.
Another important factor which can be highly variable during
infection is the presence of particular cytokines, which influence
both memory cell potential (33, 34), and the specific pool of Tmem
that develops (35). The potential for an effector T cell (Teff) to
become a Tmem cell has been defined based on the expression of
CD127 and KLRG1 (36). Teffs largely fall into one of three cate-
gories: terminally differentiated short-lived effector cells (SLECs,
KLRG1hi/CD127lo), early effector cells (EECs, KLRG1lo/CD127lo)
or memory precursor effector cells (MPECs, KLRG1lo, CD127hi).
It is the latter population, which develops into long-lived, bonafide
Tmem of various phenotypes, including TCM, TEM, and TRM.
Therefore, the formation of MPECs is a necessary step in TRM
development, although the timing in which a cell begins to express
these markers may differentially impact its memory phenotype.
MPECs can form early in the lymph node, or once at the site
of infection they can arise from EECs, which have the potential
to differentiate into both SLECs and MPECs (37). The inflam-
matory cytokine IL-12 is detectable at 48 h following influenza
infection, and is important for the development of IFN-γ produc-
ing cells early in the immune response (38). In regard to memory
development, IL-12 promotes the development of terminally dif-
ferentiated SLECs in a dose dependent manner via induction of
the transcription factor T-bet (33). Interestingly, graded induction
of IL-12 is observed after systemic infection with two different
pathogens: L. monocytogenes (LM) induces a high concentration
of IL-12, whereas vesicular stomatitis virus (VSV) induces much
lower IL-12 levels. High concentrations of IL-12 during LM infec-
tion promote a skewed development favoring SLECs while VSV
infection (lower IL-12) favored EECs (37). Since TRM cells arise
from KLRG1lo precursors (14), high levels of IL-12 would likely
negatively impact TRM development. Nonetheless, a minimum
threshold of IL-12 (and T-bet) expression is required to not only
promote the requisite development of Teff but promote migra-
tion into peripheral sites. In support of this, it has been shown
that CD103+ DCs isolated from the small intestine are capable of
producing IL-12 following TLR stimulation (39). However, high
levels of IL-12 signaling had a direct effect on CD8+ T cells, lead-
ing to the down-regulation of CXCR3, a molecule necessary for
the accumulation of antigen-specific CD8+ T cells in the airways
following influenza infection (40). These data would suggest that
CD8+ T cells at the site of priming need just the right amount
of IL-12 to reach their full TRM potential. In terms of cytokines
important for parsing Tmem into defined subsets, the common
gamma chain cytokines IL-2 and IL-15 have been shown to play a
role in CD8+ T cell differentiation into TCM and TEM cells. TCM
cells can be identified as a distinct population arising from MPECs
as early as 5 dpi, and are formed through IL-15 signaling (when
IL-2 is limited), whereas IL-2 signaling leads to TEM phenotypes
(41). As previously mentioned TCM cells develop early after infec-
tion from the MPEC population in the lymph node, and these cells
may never enter peripheral tissues. Thus, TRM cells may arise from
Teffs, which do not receive early TCM biasing signals in the lymph
node, and retain the ability to enter peripheral sites.
While the evidence we have presented thus far suggests that spe-
cific cellular interactions and cytokines present in the lymph node
at the time of priming could form a population of cells with the
potential to become TRM cells, an early development pathway com-
pletely unique to TRM remains unlikely. Traditional cell surface
markers and functional characteristics associated with Teff cells or
TEM, such as low levels of CD62L expression, are indistinguish-
able from TRM early after infection. Moreover, the prototypical
TRM cell surface marker, CD103, does not appear until after a
certain period of tissue residency in the epidermis (14). Inter-
estingly, TRM populations in the skin require the expression of
CXCR3 for entry into the epithelium and subsequent TRM dif-
ferentiation as cells lacking CXCR3 remained largely outside of
the epidermis and TRM recovered from the skin were numerically
reduced. Conversely, mice lacking CCR7 expression have CD8+
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Teffs, which fail to leave the skin via the lymphatics and harbor
larger numbers of TRM cells, suggesting environmental factors are
required for complete TRM development (14). Signals encountered
in the MdLN after respiratory infection likely generate a popula-
tion of Teff cells with the potential to enter the lung and fully
develop into true TRM cells. However, CD8+ T cells isolated from
the respiratory tract phenotypically resemble TEM cells, TRM cells,
and terminally differentiated SLECs (our unpublished observa-
tions), suggesting not all Teff that enter the lung become TRM.
More likely, cells immigrating to the respiratory tract enter as a
common TEM/RM precursor (Figure 1A). This common TEM/RM
precursor population is likely primed by CD103+ DCs, expresses
high levels of CD25, and encounters intermediate levels of IL-12,
akin to the development of TEM cells. Therefore, TRM and TEM cells
may share similar early developmental pathways, with later signals
in the lung further differentiating and diverting true TRM from a
common TEM/RM precursor. Indeed, evidence supports the devel-
opment of a common TEM/TRM precursor. As previously noted,
the development of TEM cells is dependent on IL-2 (and not IL-15)
(41) and IL-15 is also dispensable for CD8+ Tmem that develops
following a respiratory infection (42), which generates substantial
TRM compared to systemic infection (20). In contrast, systemic
infections produce large amounts of TCM cells, and Tmem in these
infections require IL-15 for maintenance over time (43). Although
the evidence suggests a common developmental pathway for TEM
and TRM cells after initial activation in the lymph node, the possi-
bility remains that they are distinct lineages by the time of lymph
node egress (Figure 1B), identifiable by phenotypic markers or
gene expression patterns yet to be discovered. Nonetheless, the
full commitment to the TRM lineage will continue in the specific
peripheral tissue, where these cells will be retained.
ENVIRONMENTAL SIGNALS COMMIT TEM/TRM PRECURSOR CELLS TO A
TRM LINEAGE
If T cell priming in the MdLN results in the migration of a com-
mon TEM/RM precursor population of cells to the lung, what
factors in the lung facilitate the development of “full-fledged”
TRM cells? At the site of infection multiple factors will continue to
influence emigrating TEM/RM precursors. Evidence in cutaneous
infection models suggests that commitment to the TRM lineage is
a two-step process characterized by the sequential up-regulation
of Bcl-2 and CD69, followed by CD103 (14). This suggests that
T cells first acquire a memory phenotype, or an increased chance
of survival, prior to differentiating into TRM cells based on the
current TRM phenotypic markers. This section will discuss the
respiratory factors that influence the transition to a memory phe-
notype and specific environmental components present in the
lung that polarize these anti-viral CD8+ T cells toward a TRM
lineage.
The inflammatory environment of the lung
The pioneer Teff cells immigrating to the lung arrive ~5–6 days
after initial respiratory infection. Prior to their arrival, innate
immune cells have accumulated, keeping viral titers low, and
as a result, some local tissue damage has occurred via cytol-
ysis of infected epithelial cells, affecting barrier function. The
inflammatory effects of this local immune response in the lung
are still very present at the time of T cell entry, and can influ-
ence the development of TRM cells. However, since anti-influenza
Teff migrate to the lung asynchronously over several days (peak-
ing at ~10 days post viral infection), all T cells do not encounter
equivalent levels of inflammation which will likely affect the fate
of individual Teff clones.
The first CD8+ Teffs to arrive at the site of infection will
encounter the greatest level of inflammation, as infectious virus
is still present (at least until ~d8 post influenza infection) and
innate effectors such as NK cells are producing local IFN-γ (38).
Inflammatory monocyte-derived DCs arrive in the inflamed lung
at the same time as Teff and function as lung APCs, amplifying
the inflammatory milieu and locally expanding the emigrating
Teff (44). Additionally, CD8
+ T cell proliferation continues in the
lung, a process requisite for viral control after influenza infection
(45). This additional expansion, however, is not without a cost.
Increased levels of cellular division is not only associated with
increased levels of apoptosis within the highly dividing popula-
tions (46), the aforementioned cytokines also promote terminal
differentiation of the T cells and the formation of KLRG1+ SLECs
(47, 48). Therefore, this early inflammatory environment skews
cells away from becoming memory cells, yet may paradoxically
pave the way for resolution from infection and inflammation so
that later immigrants may develop into Tmem.
CD8+ Teff themselves produce cytokines in the lung, including
IL-2, IFN-γ and TNF-α which enhance the overall inflamma-
tory response (49). Interestingly, while CD8+ T cells activated in
lymph nodes rapidly gain the ability to produce the inflammatory
cytokine IFN-γ, entry into the lung tissue imparts IL-10 produc-
tion (50, 51) in a manner seemingly dependent on the inflam-
matory lung environment (52), indicating that an enhanced acti-
vation status resulting from high levels of inflammation induces
the CD8+ T cells to produce regulatory cytokines. IL-10 is also
produced at high levels by regulatory T cells (Tregs) activated in
the lung following influenza infection (53). The production of
regulatory cytokines by Tregs and CD8+ T cells is important to
initiate “dampening” the immune responses in the lung to pre-
vent excessive damage and loss of function of this essential organ.
Importantly, the production of IL-10 can directly impact the devel-
opment of memory cells by inducing MPEC populations in a
STAT3 dependent manner (54), however, it is unclear whether
IL-10 has any direct consequences on the development of TRM.
A variety of other cytokines produced after influenza infection
is known to modulate anti-viral CD8+ T cell responses. Thymic
stromal lymphopoietin (TSLP), an epithelial derived cytokine that
can be produced in the infected lung (55, 56), promotes expan-
sion of the CD8+ T cells at the site of infection directly (56)
and indirectly via CD11b+ inflammatory DCs (57). Additionally,
transpresentation of IL-15 by pulmonary DCs has been shown
to increase the survival of Teffs (58) and is an important com-
ponent of TRM development in the skin (14). However, IL-15
does not seem necessary for the overall development of mem-
ory in the lungs or the airways following influenza infection (42),
although this study as well as the TSLP studies did not address
TRM populations specifically.
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Localization as an important step in development of TRM cells
As residence at the peripheral site is a requisite for TRM develop-
ment, cells destined to become TRM cells must first gain access
into peripheral tissues, often into physically restricted areas such
as within an epithelial layer or closely associated with the under-
lying basil lamina (within the parenchyma). The route of migra-
tion used by T cells trafficking to the lung, however, is not well
understood. Cells can enter the lung via two circulatory systems:
the bronchial system, which provides oxygenated blood to the
lung tissue, and the pulmonary circulation, which includes ves-
sels that bring deoxygenated blood to alveoli and subsequently
drain oxygenated blood back to the heart (59). The lung epithe-
lium surrounding the airway spaces share a fused basal lamina
with the adjacent capillary endothelium to allow gas exchange and
could facilitate direct blood to airway traffic. Because pulmonary
vessels are small in diameter and thin walled, blood pressure in
these vessels is relatively low, thus allowing lymphocytes to tra-
verse the endothelium independent of the multistep paradigm
described for lymphocyte migration through larger vessels, which
are dependent on selectins, integrins, and chemokines (60). How-
ever, histological sections of lung tissues depict memory cells
localized close to the airways, but within the lung parenchyma,
evoking a blood→ lung→ airway route (19, 61).
Broadly speaking, activated CD8+ Teffs cells can gain access to
peripheral sites by virtue of their expression of CD11a and CD44
with concomitant loss of CD62L expression on their cell surface
(60, 62).While access into distinct anatomical sites within other
mucosal tissues such as the skin and gut is highly correlated with
expression of tissue-specific homing receptors (63–65), analogous
molecules have not yet been identified for lung homing CD8+ T
cells. Nonetheless, some chemotactic signals are associated with
Teff migration into inflamed lung tissues including CXCR3 (66)
and CXCR6 (67). CXCR6 is specifically up-regulated on CD8+ T
cells isolated from the lung and lung airways following intranasal
immunization and mice lacking CXCR6 have reduced protection
against tuberculosis challenge (67), indicating that CXCR6 expres-
sion may be important for the establishment of CD8+ T cells at
sites of protection. The expression of CXCR3 is important to estab-
lish migration of CD8+ T cells specifically to the airways (68).
While TRM populations were not assessed in this study, CXCR3−
antigen-specific CD8+ T cells isolated from the lung expressed
lower levels of CD69 than WT cells occupying the airways where
antigen is present. CD69 expression is upregulated on TRM popula-
tions, and contact with antigen has been suggested to be necessary
for TRM formation (8). Therefore, expression of CXCR3 may be a
requirement for the development of TRM cells in the lungs, akin
to the requirement for CXCR3 in the skin (14).
As influenza virus replicates primarily in epithelial tissue, the
localization of CD8+ T cells adjacent to antigen may expose them
to unique cytokines available in and near the epithelium such
as TGF-β. TGF-β plays a role in both the contraction of effector
T cells (69) and the establishment of TRM cells by inducing the
expression of CD103 (70). The role of TGF-β in the development
of TRM cells has been well described in the intestinal mucosa and
the skin, and has also been implicated in the development of TRM
in the lung (71). Although TGF-β can be transiently activated by
influenza virus (72, 73), it likely has lower constitutive production
in the lung than other barrier sites as over-expression of TGF-β
can promote pulmonary fibrosis and lung disease (74). Due to the
localization of TGF-β production, CD103 expression may be spe-
cific to only those cells, which are found within epithelial layers and
not necessary for TRM in the lung parenchyma, a concept discussed
later in more detail. Interestingly, following influenza infection a
large majority of antigen-specific CD8+ T cells begin to express the
α1β1 integrin VLA-1 (61). Teffs localized cells to the collagen-rich
areas near the airways and basement membranes that are VLA-1+
have a survival advantage over those that do not express VLA-1 at
the peak of the CD8+ T cell response (61). The localization and
retention of cells within the lung parenchyma, as well as the sur-
vival advantage may make VLA-1 expression a unique marker for
cells destined to become lung TRM cells. However, this possibility
has yet to be explored.
PART II: CHARACTERISTICS AND MAINTENANCE OF
COMMITTED CD8+ TRM IN THE LUNG
Following the resolution from infection, antigen-specific CD8+ T
cells will persist at the site of infection (19). As previously noted,
these Tmem cells exist in the lung in two basic compartments,
the airways and the lung parenchyma. Airway CD8+ T cells exist
outside of the body, within the lumen of the respiratory tract,
or they can exist much like they do in the intestinal epithelium
as intraepithelial cells. Cells within the airways, and very likely
some intraepithelial cells, can be isolated by performing a bron-
choalveolar lavage (BAL), while the remaining parenchyma cells
can be isolated through a process involving the enzymatic diges-
tion of collagen. Additionally the localization and characterization
of these cell populations can be defined by microscopic analysis
of lung tissue sections, although phenotyping cells by this method
is limited. It is important to distinguish between these two popu-
lations of cells in the discussion of TRM, as airway cells are likely
comprised of both true TRM cells and circulating Tmem, which
migrate to the airways following the resolution of infection.
Cells in the airways are subject to the external environment of
the lung, where mucous and pulmonary surfactants decrease the
potential for their long-term persistence. Therefore, it is thought
that memory CD8+ T cells in the lung airways, at least for some
period of time, are partially maintained by the continual recruit-
ment to the airways. In support of this, Slutter et al. showed that
CXCR3 is required for the continual recruitment of cells into the
airways, and that loss of CXCR3 expression results in the accel-
erated loss of antigen-specific CD8+ T cells specifically from the
airways (40). Tracking the entry of Tmem from the circulation is
also possible by monitoring CD11a expression, which is lost ~40 h
after CD8+ T cell emigration into the airways (75). Indeed, when
Tmem are extracted from the airways (up until at least 13 months
post infection), portions of the antigen-specific CD8+ T cells
express high levels of CD11a. Together, these data confirm that
at least a proportion of airway CD8+ cells may not be bona fide
TRM based on presence within this site alone. In support of this
argument, CD103 expression is reduced on antigen-specific Tmem
isolated from the airway when compared to Tmem isolated from
the lung parenchyma both in terms of frequency (11) and on a
per cell basis (76). Finally, while evidence suggests that a circulat-
ing population of cells is actively recruited into the lung airways
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during steady state conditions (40, 75) it is clear that these recruits
are not sufficient (either in number or function) to provide pro-
tection against heterosubtypic influenza challenge, as protection
wanes while recruitment continues. Perhaps the limited migra-
tion and supplementation of competent Tmem cells from within
the lung parenchyma may augment this pool and maintain het-
erosubtypic immunity, at least temporarily. However, cell tracking
studies have not confirmed this possibility.
Tmem also exist in the respiratory tract within the lung tissue
or parenchyma. As the lung is a highly vascularized organ, it can
be difficult to discern at time of tissue harvest, which antigen-
specific cells are trafficking through the vasculature of the lung
(trapped within small capillaries) and which are truly within the
parenchyma. Experiments using intravascular staining whereby
antibodies are injected directly into the blood stream immediately
before the lungs are examined to “tag” circulating cells demon-
strated a large number of cells isolated from the lung tissue are
circulating cells (naïve or TEM) despite perfusion. This method
has been useful in characterizing both CD4+ (77, 78) and CD8+
(11) TRM cells in direct contrast to the circulating pool. Using this
method to distinguish circulating vs. resident cells has, and will,
continue to provide a clearer picture of what TRM cells look like in
the resting lung.
Microscopic analysis of lung tissue sections has also been useful
in determining the precise localization of TRM in the respiratory
tract to gain better insight regarding the cellular associations and
tissue microarchitecture, which may be important for supporting
TRM development and/or survival. Turner et al. showed that CD4+
TRM cells established following influenza infection were clustered
together in the lungs, in regions both close to the airways and to the
pulmonary blood vessels (78). This would position the cells in an
ideal place to encounter antigen entering the body. The clustering
of cells in this location is not a new observation, nor is it exclusive
for the CD4+ T cell population. In 2004, Ray et al. showed that
influenza specific CD8+ T cells persisted in the highly collage-
nized area between the airways and the blood vessels, and that this
retention was dependent on the expression of VLA-1 (61). VLA-1
binds to type IV and type I collagen (79, 80), which are impor-
tant structural components of the lung interstitium, specifically
between the bronchi and the vasculature, and the basement mem-
branes of both the pulmonary vasculature and the epithelium of
the airway, respectively (81, 82). The co-localization of TRM and
collagen below the epidermal cell layer of the airways shows that
TRM cells also exist within the lung parenchyma. The collagen-rich
environment of the lung may provide a framework or scaffold in
which TRM cells can persist close to the site of antigen acquisition,
yet not actually within the epithelial layer of the lung where they
may be subject to the harsh environment of the airways. Addition-
ally, it is quite possible that this collagen matrix could also trap or
capture soluble growth factors important for TRM maintenance.
THE PERSISTENCE OF TRM CELLS IN THE RESPIRATORY TRACT: ROLE OF
THE LUNG ENVIRONMENT
Like other mucosal barrier sites, the resting lung is engaged in a
constant balancing act regarding immunity and tolerance. It is esti-
mated that we breathe in 10,000 l of air per day, with each breath
containing a plethora of allergens, environmental pollutants, and
pathogens. Inappropriate response to non-harmful antigens could
lead to persistent inflammation and pulmonary disease. To pre-
vent this, multiple layers of innate protection exist in the lung
to preclude any inappropriate initiation of an immune response.
The most basic of these is the mucosal barrier itself. The lining
of the upper respiratory tract is composed of ciliated epithelial
cells and mucus-secreting goblet cells, which together function as
a “mucociliary escalator” facilitating expulsion of these innocuous
agents, as well as some commensal organisms, out of the respi-
ratory tract without activation of the adaptive immune response.
However, the mucus would also prevent TRM cells from persisting
in the airways of the upper respiratory tract, leading to the accu-
mulation of TRM either within the epithelium, the parenchyma,
or in the airways of the lower respiratory tract. While the lower
respiratory tract does not contain mucous, it is characterized by
numerous “pockets” where gas exchange occurs termed alveoli.
The cells lining the alveoli are specialized epithelial cells known as
type I and type II alveolar epithelial cells, which form the struc-
tural architecture of the alveoli and secrete immunosuppressive
pulmonary surfactants, respectively (83). The role that these lung
derived factors may play on CD8+ T cells at the site is further
complicated by conditions of an inflamed lung, such as asthma
and allergy. Allergens can induce the upregulation of pulmonary
surfactants, which in turn can protect against allergic disease via
local IL-13 inhibition (84). Due to the proximity of surfactants and
TRM cells in the lower respiratory tract, and the essential role for
surfactants in regulating respiratory inflammation, it is possible
that TRM persistence could be dynamically regulated by perturba-
tion in surfactant (and mucus) activity. However, this has not been
analyzed.
TRM persist long-term in many non-lymphoid tissues, albeit
with different kinetics. For example, VSV-specific TRM cells exist
as long as 120 dpi in the brain (8) while cutaneous herpes simplex
virus TRM cells persist for the lifetime of a mouse (85). This is
shown to occur independently of increased proliferation (8, 15)
and maintained populations are not dependent on replenishment
from lymphoid organs (6, 78). Perhaps somewhat unique to the
respiratory tract is that Tmem cells within this site appear to have
a limited life-span, steadily decreasing over time (19). The lack
of long-term survival of Tmem cells lung airways, and perhaps
certain populations in the lung itself, has functional consequences
since heterosubtypic immunity against influenza viruses is lost ~4–
6 months post infection (18). Moreover, this loss of anti-influenza
immunity is coordinate with substantial loss in CD8+ Tmem cells
of the airways, despite stable numbers in the spleen (19) and the
continual recruitment of cells from the circulation into the airways
(40, 75). While these former studies did not directly assess the role
of TRM cells, recent evidence suggests that protective heterosub-
typic immunity against influenza infection is mediated solely by
TRM, as the ability to control viral titers and protect from severe
disease is gradually lost along with TRM cells in the airways (20).
Yet, the question of why TRM cells do not persist in the lung and
lung airways to the extent that they do in other tissues remains
unanswered. Interestingly, following influenza infection lung TRM
cells retain expression of interferon-induced transmembrane pro-
tein IFITM3, which imparts cells with a survival advantage in the
face of viral infection (76). This increased survival mechanism
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Table 1 | Factors associated with the positioning and survival of defined pools of memory CD8+ T cells in specific anatomical sites.
CD127 CD122 PD-1 CD103 CXCR3 IFITM3 CD69 CD27 VLA-1
TEM +++ +++ − − −/+ − +
TCM +++ +++ − − −/+ − ++
TRM Lung −/+ + ++ −/+ +++ +++ +++ ++/+++ +++
TRM Gut +/++ + +++ +++ + ++*
TRM Skin + + +++ +++ +++ +*
TRM Brain ++ + ++ +++ +++ +++ −
−absent, +low levels, ++moderate levels, +++high levels, blank=no data for this tissue.
*Indicates data is from human studies, all other data in table obtained from mouse models.
may be particularly important at this site, due to the regularity at
which respiratory infections are acquired. The unique properties
of respiratory TRM cells have provided some insight into why their
persistence in the lungs is limited (Table 1).
The cytokines IL-7 and IL-15 are requisite for the development
and maintenance of memory CD8+ T cells after systemic infec-
tion (35, 86). However, what role, if any, these cytokines play in
the maintenance of TRM cells in the lung has not been defined.
In most sites assessed to date, TRM cells express reduced levels of
CD127, as compared to TCM and TEM cells. Concurrently, CD8+
T cells in the lung airways express reduced levels of CD127 (11, 87,
88) as do cells in the lung parenchyma, although to a lesser extent
(56). Like CD11a, it is possible that CD127 is cleaved from CD8+
T cells in the airways, leaving these cells incapable of receiving pro-
liferative or survival signals, either from IL-7 or from TSLP, which
has been shown to be produced constitutively in the gut (89),
and in the lung during both resting conditions and after inflam-
matory stimuli (56). IL-15 has been shown to be dispensable for
the development and maintenance of memory cells that develop
from respiratory infections and CD122 is lost from CD8+ T cells
within the respiratory tract (87). Furthermore, CD122 or the beta
chain of the IL-15R, which signals to memory CD8+ T cells is
expressed at lower levels on TRM isolated from the epithelium of
the small intestine (90). A recently described pool of TRM isolated
from secondary lymphoid organs are maintained independently
of IL-15 and even found in increased numbers in mice lacking IL-
15 (91). Therefore, IL-15 appears to be uniformly dispensable for
the maintenance of TRM cells, and while levels of CD127 on TRM
cells is more variable, the near complete loss of this receptor in the
respiratory tract may provide one mechanism in which CD8+ T
cells at this site have decreased sustainability. However, it should
be noted that TRM cells from the brain do not respond to IL-7 or
IL-15 ex vivo, unlike splenic memory cells, which show increased
survival upon exposure to these cytokines (16), indicating that
perhaps the survival of TRM cells is completely independent of
classical cytokine memory signals.
The maintenance of CD8+ T cells in the lungs has also been
attributed to residual antigen found in the MdLN for ~2 months
post influenza infection (92). Influenza antigens have also been
detected in the lung tissue itself for 30 days within focal inflam-
matory structures (93), reminiscent of inducible bronchus associ-
ated lymphoid tissue (iBALT). iBALT develops following influenza
infection and has similar structure to lymph node tissue, such as
defined B cell follicles and the formation of germinal centers sur-
rounding DCs; this structure contributes to the proliferation of
B and T cells during primary influenza infection and can be pro-
tective in mice where other lymphoid organs are lacking (94). As
the timing of loss of residual antigen coincides with the loss of
protective heterosubtypic immunity, it has been hypothesized that
antigen is necessary for the persistence of Tmem in the lung and
lung airways. In support of this possibility, TRM cells in the lung
express PD-1 (20), which may indicate continued exposure to anti-
gen. While certain TRM populations have been shown to persist in
the absence of antigen (8, 31) definitive studies have not been car-
ried out for TRM cells in the lung to rule this out as a mechanism
for maintenance.
It is likely in humans that the maintenance and survival of
TRM cells may be much different than what is observed in mice.
As previously mentioned, constant antigenic stimulation, aller-
gic inflammation, and relatively common airway disorders such as
asthma will influence the lung environment in ways that will affect
many indigenous respiratory cells. In addition, the regularity of
respiratory infections in humans will result in the accumulation
of many pools of clonally diverse antigen-specific cells, recognizing
a plethora of pathogens. de Bree et al. showed that influenza and
respiratory syncytial virus-specific CD8+ T cells were enriched
in the human lung compared to the circulation (95). In direct
contrast, antigen-specific CD8+ T cells that developed from the
blood-borne pathogens cytomegalovirus and Epstein-Barr virus
equilibrated between the blood and lung of these patients (95).
The accumulation of CD8+ T cells in the lung due to respiratory
infection would certainly lead to large numbers of TRM cells pop-
ulating the human lung during steady state conditions. Indeed,
studies have determined that CD103+αβ TCR CD8+ T cells com-
prise about 1/3 of the total CD8+ T cell population in the human
lung (96), or over 10 billion total cells (97). However, the history
of human lung TRM (when developed/how long maintained) and
how the history of individual clones correlates with acquisition
of specific infections is difficult to determine. Furthermore, in
humans, the survival of these pools may be affected by attrition
resulting from heterologous infections. In these scenarios, either
competition for resources in distinct environmental niches or by
bystander apoptosis via cytotoxic factors present at the time of the
new viral infection may deplete previously existent TRM pools (98).
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CONCLUDING REMARKS
The study of TRM cells is in its infancy. As we continue to ana-
lyze this unique lineage of memory cells, we will certainly deepen
our understanding of TRM biology in unique sites such as the
respiratory tract and perhaps better understand how to selec-
tively manipulate this pool for development of vaccines. While
the defining characteristic of what makes a cell a TRM cell is
quite clear (i.e., long-term residence at a site), some of the mark-
ers currently used to distinguish TRM cells, most notably CD103,
only recognize a subset of TRM cells localized to the (respiratory)
epithelium. This leaves a large population (anywhere from 50 to
90% of TRM cells in the lung) excluded from studies. Thus, overall
TRM frequency can only be confirmed using complicated trans-
fer and cell tracking experiments, warranting the need for more
definitive phenotypic markers to readily identify TRM. Moreover,
understanding the environment in which TRM cells at specific
sites reside will be key to developing phenotypic definitions of
these cells, as markers vary between anatomical locations. In the
case of the lung, this particular environment has many mech-
anisms in place to suppress inflammation and any inadvertent
immunopathology. Thus, while higher numbers of TRM cells at
the site of infection may be ideal for protection against dis-
ease, tight regulation of the number, and longevity of TRM cells
at this site may be essential for tissue function. This may be
especially relevant in the context of human disease, where res-
piratory infections are commonplace and populations of TRM
are not only numerically enhanced but very likely dynamically
regulated.
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